Oqory to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Oqory, Inc., a private biopharmaceutical company dedicated to developing next-generation antibody drug conjugates (ADCs) for the treatment of cancer, today announced that Michael King, Chief Executive Officer, will present data at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference.
Details are as follows:
Date: Wednesday, February 12, 2025
Time: 12:40 PM ET
Webcast link for conference participants:
https://wsw.com/webcast/oppenheimer39/oqo/2580248
About Oqory, Inc.
Oqory, Inc. is an innovator in the field of ADCs with expertise in advancing targeted cancer therapies. The Company’s pipeline includes multiple ADC programs, with two currently in clinical development and several next-generation ADCs in preclinical stages. These programs are designed to address critical unmet needs in indications such as breast cancer, non-small cell lung cancer, small cell lung cancer, multiple myeloma, and other metastatic solid tumors. Powered by a proprietary ADC platform, Oqory is focused on delivering therapies that improve outcomes for patients with cancer.
Oqory is based in San Diego, California.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250211204384/en/
Distribution channels:
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Submit your press release